Detalhe da pesquisa
1.
Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care: A Randomized Pilot Study.
Oncol Res Treat
; 45(3): 118-129, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34818660
2.
Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
Lung Cancer
; 170: 165-175, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35803041
3.
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.
J Pers Med
; 12(1)2022 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35055387
4.
Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Oncol Res Treat
; 44(9): 495-502, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34320493
5.
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
J Thorac Oncol
; 16(11): 1952-1958, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34245914
6.
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.
Cancers (Basel)
; 11(6)2019 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31212989
7.
Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease.
Cancers (Basel)
; 10(12)2018 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30572662
8.
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
J Thorac Oncol
; 13(12): e243-e246, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30205165